Dupilumab Reduces Biomarkers Indicative of Type 2 Inflammation in Children Aged ≥ 6 Months to < 6 YearsWith Moderate-to-Severe Atopic Dermatitis

被引：0
|
作者：
Pinter, Andreas [1 ]
Paller, Amy [2 ,3 ]
Guttman-Yassky, Emma [4 ,5 ]
Boguniewicz, Mark [6 ,7 ]
Sun, Yiping [8 ]
Wolfe, Kelley [9 ]
Dillon, Myles [8 ]
机构：
[1] Univ Hosp Frankfurt Main, Frankfurt, Germany
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Ann & Robert H Lurie Childrens Hosp, Chicago, IL USA
[4] Icahn Sch Med Mt Sinai, Med Ctr, New York, NY USA
[5] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA
[6] Natl Jewish Hlth, Denver, CO USA
[7] Univ Colorado, Sch Med, Denver, CO USA
[8] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[9] Sanofi, Bridgewater, MA USA
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P155
引用
收藏
页码：100 / 100
页数：1
相关论文
共 50 条
  • [41] Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients
    Achten, Roselie
    Thijs, Judith
    van Luijk, Chantal
    Knol, Edward
    Delemarre, Eveline
    de Graaf, Marlies
    Bakker, Daphne
    de Boer, Joke
    van Wijk, Femke
    de Bruin-Weller, Marjolein
    CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (02): : 239 - 243
  • [42] Laboratory Safety From a 16-week Phase 3 Study of Dupilumab in Patients Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis
    Pinter, Andreas
    Paller, Amy
    Wollenberg, Andreas
    Siegfried, Elaine C.
    Gonzalez, Mercedes E.
    Lockshin, Benjamin
    Khokhar, Faisal A.
    Chen, Zhen
    Gonzalez, Tayler
    Prescilla, Randy
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 88 - 89
  • [43] Laboratory safety from a 16-week phase 3 study of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
    Paller, Amy S.
    Wollenberg, Andreas
    Siegfried, Elaine C.
    Gonzalez, Mercedes E.
    Lockshin, Benjamin
    Khokhar, Faisal A.
    Chen, Zhen
    Gonzalez, Tayler
    Prescilla, Randy
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [44] Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
    Jackson, Daniel J.
    Bacharier, Leonard B.
    Phipatanakul, Wanda
    Sher, Lawrence
    Domingo, Christian
    Papadopoulos, Nikolaos
    Modena, Brian
    Li, Ning
    Xia, Changming
    Kamal, Mohamed A.
    Dillon, Myles
    Wolfe, Kelley
    Gall, Rebecca
    Amin, Nikhil
    Mannent, Leda P.
    Laws, Elizabeth
    Rowe, Paul J.
    Jacob -Nara, Juby A.
    Deniz, Yamo
    Lederer, David J.
    Hardin, Megan
    Xu, Christine
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (01) : 44 - +
  • [45] Dupilumab provides sustained improvement of sleep disturbance in children ≥6 years with severe atopic dermatitis (AD) and adolescents with moderate-to-severe AD
    Paller, A. S.
    Wollenberg, A.
    Simpson, E. L.
    Beck, L. A.
    Chih-ho, Hong H.
    Marcoux, D.
    Bastian, M.
    Chen, Z.
    Levit, N. A.
    Bansal, A.
    Rossi, A. B.
    Chao, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 97 - 98
  • [46] Dupilumab efficacy and safety up to 2 years in children aged 6 months to 5 years with atopic dermatitis
    Paller, Amy S.
    Simpson, Eric L.
    Siegfried, Elaine C.
    Cork, Michael J.
    Arkwright, Peter D.
    Pinter, Andreas
    Dubost-Brama, Ariane
    Laws, Elizabeth
    Chen, Zhen
    Bansal, Ashish
    Prescilla, Randy
    Nguyen, Tien, V
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 78 - 79
  • [47] Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Okragly, Angela
    Sun, Zhe
    Mena, Laura Rebeca
    Hahn, Nathan
    Nickoloff, Brian J.
    Siu, Kimberly
    Gallo, Gaia
    Wolf, Eric
    Eyerich, Kilian
    Aparici, Monica
    Benschop, Robert J.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II4 - II5
  • [48] Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, E.
    Okragly, A.
    Sun, Z.
    Mena, L. R.
    Hahn, N.
    Nickoloff, B. J.
    Siu, K.
    Gallo, G.
    Wolf, E.
    Eyerich, K.
    Aparici, M.
    Benschop, R. J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S364 - S364
  • [49] Real-life experience with dupilumab in 56 children and adolescents aged 2 to 17 with uncontrolled moderate-to-severe atopic dermatitis
    Colonna, Cristiana
    Monzani, Nicola A.
    Quattri, Eleonora
    Montefusco, Francesca
    Cavalli, Riccardo
    ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2024, 159 (06) : 694 - 695
  • [50] Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, E.
    Okragly, A.
    Sun, Z.
    Mena, L.
    Hahn, N.
    Nickoloff, B.
    Siu, K.
    Gallo, G.
    Wolf, E.
    Eyerich, K.
    Aparici, M.
    Benschop, R.
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (03)
12345